Abstract
Purpose To report regression of corneal stromal neovascularizations with the use of topical cyclosporine 0.05% in a corneal transplant patient performed for fungal corneal ulcer. Design Case report. Methods A 14-year-old boy treated for fungal corneal ulceration developed 360° corneal stromal neovascularization peroperatively. Topical cyclosporine 0.05% was used to decrease the risk of rejection. Results The neovascularizations regressed totally within 2 months and no signs of graft rejection were present at 6 months follow up. Conclusion Topical cyclosporine 0.05% may result in regression of stromal corneal neovascularizations and help to reduce the risk of graft rejection in selected cases.
Similar content being viewed by others
References
Randleman JB, Stulting RD (2006) Prevention and treatment of corneal graft rejection: current practice patterns (2004). Cornea 25:286–290
Heiligenhaus A, Steuhl KP (1999) Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Graefes Arch Clin Exp Ophthalmol 237:435–438
Sonoda KH, Nakao S, Nakamura T et al (2005) Cellular events in the normal and inflamed cornea. Cornea 24:S50–S54
Hernandez GL, Volpert OV, Iniguez MA et al (2001) Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 193:607–620
Perry HD, Doshi SJ, Donnenfeld ED, et al (2002) Topical cyclosporin A in the management of therapeutic keratoplasty for mycotic keratitis. Cornea 21:161–163
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sonmez, B., Beden, Ü. & Erkan, D. Regression of severe corneal stromal neovascularization with topical cyclosporine 0.05% after penetrating keratoplasty for fungal corneal ulcer. Int Ophthalmol 29, 123–125 (2009). https://doi.org/10.1007/s10792-007-9180-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-007-9180-4